Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Meningococcal vaccine groups B and C - GlaxoSmithKline

Drug Profile

Meningococcal vaccine groups B and C - GlaxoSmithKline

Alternative Names: Cuban meningococcal BC vaccine; VA-MENGOC-BC

Latest Information Update: 17 Nov 2014

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Finlay Institute of Cuba; Nonindustrial source
  • Developer Finlay Institute of Cuba; GlaxoSmithKline Biologicals; Nonindustrial source
  • Class Meningococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Meningococcal group B infections; Meningococcal group C infections

Most Recent Events

  • 12 Nov 2014 Meningococcal vaccine groups B and C licensed to Abivax in Asia and Latin America
  • 28 Feb 2005 GlaxoSmithKline has filed an MAA with the EMEA in Europe for Meningococcal group B and C infections
  • 26 Nov 2001 A study has been added to the Bacterial Infections immunogenicity section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top